MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Total Current Liabilities
All obligations due within one year.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 92.3% from a year ago
Total current liabilities stood at $46.11M at the end of Q1 FY2026, up 92.3% from a year earlier and up 1.4% from the prior quarter. Over 3 fiscal years it compounded at +81.0% a year.
Context
- Total current liabilities amounted to 11.5% of total assets at the end of Q1 FY2026, up 6.8 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +92.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 45.48M USD
- Year-over-year change
- +102.4%
- 4-year CAGR
- +21.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.48M | +102.4% |
| FY2024 | 2024-12-31 | 22.46M | +125.4% |
| FY2023 | 2023-12-31 | 9.97M | +30.0% |
| FY2022 | 2022-12-31 | 7.67M | -63.6% |
| FY2021 | 2021-12-31 | 21.09M | — |
Total Current Liabilities vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's Mar 2026 total current liabilities of $46.11M is the 3rd highest of the 11 companies compared; the peer median is $29.58M.
- Its year-over-year change of +92.3% is the highest of 10, against a peer median of +27.2%.
- Total current liabilities amounts to 11.5% of total assets for MLTX, versus a peer median of 10.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $130.74M | +58.8% | +7.0% | 10.9% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $76.23M | -10.9% | +76.4% | 13.6% |
| Mar 2026 | $46.11M | +92.3% | +81.0% | 11.5% | |
| Mar 2026 | $41.7M | -5.3% | +14.0% | 12.6% | |
| Jun 2026 | $34.39M | +71.1% | +55.2% | 2.8% | |
ORKAOruka Therapeutics, Inc. | Sep 2026 | $31.78M | +51.6% | +138.6% | 2.6% |
| Mar 2026 | $27.37M | +27.2% | +9.3% | 13.8% | |
| Dec 2025 | $13.61M | +60.9% | -4.5% | 24.3% | |
| Jun 2026 | $12.62M | — | — | 9.8% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -5.7% | 5.1% |
| Mar 2026 | $3.35M | -44.3% | -54.9% | 5.3% | |
| Peer median (excluding MLTX) | $29.58M | +27.2% | +9.3% | 10.4% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.04M | 39.51M | 451.17M | 180.43M | 334.52M |
| Short-term Investments | 0 | 32.61M | 59.84M | 267.6M | 59.45M |
| Net Receivables | 148.77K | 217.13K | 1.06M | 2.84M | 4.87M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 9.64M | 76.51M | 514.17M | 474.29M | 421.69M |
| Property, Plant & Equipment (Net) | 45.74K | 331.97K | 3.95M | 3.64M | 2.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 115.04M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (115.04M) | (0) | 8.42M | 0 | 596K |
| Total Non-current Assets | 45.74K | 331.97K | 12.37M | 3.64M | 2.74M |
| Total Assets | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Account Payables | 1.23M | 47.48K | 1.46M | 8.68M | 0 |
| Short-term Debt | 15M | 0 | 0 | 0 | 1.23M |
| Tax Payables | 63.92K | 109.83K | 367.98K | 642.11K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.3M | 109.83K | 2.78M | 4.24M | 40.83M |
| Total Current Liabilities | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
| Long-term Debt | 0 | 0 | 0 | 0 | 74.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.86K | 282.21K | 583.43K | 620.68K | (374K) |
| Total Non-current Liabilities | 239.86K | 411.16K | 3.08M | 2.08M | 74.47M |
| Total Liabilities | 21.33M | 8.08M | 13.05M | 24.54M | 119.95M |
| Common Stock | 38.54K | 5.27K | 6.3K | 6.39K | 7K |
| Retained Earnings | (53.64M) | (80.65M) | (116.66M) | (235.59M) | (462.91M) |
| Accumulated OCI | (168.18K) | 350.95K | 2.36M | 5M | 604K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 19.87M | 17.82M | 6.57M | 0 |
| Total Equity | (11.65M) | 68.77M | 513.49M | 453.39M | 304.48M |
| Total Debt | 15M | 282.58K | 3.7M | 2.83M | 75.71M |
| Net Debt | 6.96M | (39.22M) | (447.47M) | (177.6M) | (258.81M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.